We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+13.2%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$581M
AUM Growth
+$65.9M
Cap. Flow
-$17.7M
Cap. Flow %
-3.04%
Top 10 Hldgs %
83.03%
Holding
29
New
5
Increased
5
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$31M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$9.66M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$7.26M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$6.78M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.44M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$21.1M
2
ARRY
Array Biopharma Inc
ARRY
+$8.39M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$7.51M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.72M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$931K

Sector Composition

Rank Sector Weight
1 Healthcare 79.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
26
Enanta Pharmaceuticals
ENTA
$366M
– –
-153,500
Closed -$2.72M
PTLA
27
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-305,786
Closed -$7.51M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2013 Portfolio in Review

As of Q3 2013, BVF Inc held 29 positions worth $581M, up 13% from $515M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

BVF Inc withdrew a net $17.7M in Q3 2013, closing 3 positions and reducing 3 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $7.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier.

Against the trend, BVF Inc opened a new position in Tobira Therapeutics, Inc. Common Stock worth $11.1M.

  • BVF Inc's largest Q3 2013 buy was Tobira Therapeutics, Inc. Common Stock: 184,343 shares worth $11.1M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q3 2013, an estimated $31M increase.
  • BVF Inc's biggest Q3 2013 reduction was Ligand Pharmaceuticals, cutting an estimated $21.1M.
  • BVF Inc fully exited Portola Pharmaceuticals, Inc. in Q3 2013, selling an estimated $7.51M.
  • BVF Inc's ten largest holdings make up 83% of its $581M portfolio in Q3 2013.
  • BVF Inc opened 5 new positions and closed 3 in Q3 2013.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $581M.

Based on BVF Inc's 13F filing for Q3 2013, filed 14 Nov 2013.